The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

April 30, 2024

Study Completion Date

July 30, 2024

Conditions
Hypertrophic Cardiomyopathy
Interventions
DRUG

Trientine

Trientine dihydrochloride is a white to pale yellow crystalline hygroscopic powder.

DRUG

Placebo

Placebo capsule, manufactured with the exact components of the trientine capsules, without the active ingredient / investigational medicinal product.

Trial Locations (7)

AB25 2ZN

NHS Grampian, Aberdeen

LE3 9QP

University Hospitals of Leicester NHS Foundation Trust, Leicester

L14 3PE

Liverpool Heart and Chester Hospital NHS Foundation Trust, Liverpool

SW3 6NP

Royal Brompton and Harefield NHS Foundation Trust, London

M23 9LT

Manchester University NHS Foundation Trust, Manchester

NE29 8NH

Northumbria Healthcare NHS Foundation Trust, North Shields

OX3 9DU

Oxford University Hospitals NHS Foundation Trust, Oxford

All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

collaborator

University of Manchester

OTHER

collaborator

University of Liverpool

OTHER

collaborator

Univar BV

INDUSTRY

collaborator

University of Oxford

OTHER

lead

Manchester University NHS Foundation Trust

OTHER_GOV

NCT04706429 - The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter